Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Jun;76(12):6408-12.
doi: 10.1128/jvi.76.12.6408-6412.2002.

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

Paul W H I Parren  1 , Tom W Geisbert, Toshiaki Maruyama, Peter B Jahrling, Dennis R Burton
Affiliations

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

Paul W H I Parren et al. J Virol. 2002 Jun.

Abstract

A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.

PubMed Disclaimer

References

    1. Anonymous. 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull. W. H. O. 56:271-293. - PMC - PubMed
    1. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, Y. Lu, J. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206. - PubMed
    1. Borisevich, I. V., V. V. Mikhailov, V. P. Krasnyanskii, V. N. Gradoboev, E. V. Lebedinskaia, N. V. Potryvaeva, and G. D. Timan'kova. 1995. Development and study of the properties of immunoglobulin against Ebola fever. Vopr. Virusol. 40:270-273. - PubMed
    1. Bowen, E. T. W., G. Lloyd, G. Platt, L. B. McArdell, P. A. Webb, and D. I. H. Simpson. 1978. Virological studies on a case of Ebola virus infection in man and in monkeys, p. 80-85. In S. R. Pattyn (ed.), Ebola virus haemorrhagic fever. Elsevier, Amsterdam, The Netherlands.
    1. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1999. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179(Suppl. 1):S248-S258. - PubMed

Publication types

MeSH terms